Sellas rises on preclinical data for blood cancer drug

Sellas Life Sciences

27/11/2024 15:39

** Cancer drug developer Sellas Life Sciences Group's
 SLS.O  shares rise 3.7% to $1.24
    ** Co says preclinical data showed its experimental drug,
SLS009, demonstrated high efficacy in treating solid cancers
with mutations in the ASXL1 gene
    ** Late last year, U.S. Food and Drug Administration granted
SLS009 "orphan drug" status
    ** Orphan drug status is given to drugs that treat rare
conditions, and are protected through a series of government
incentives once in market
    ** Including session's gains, stock has risen 16.5% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))